Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

Novartis pulls fevipiprant development in asthma following trial failure

December 16, 2019 Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, pharma, trial failure

Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels …
News

Biogen terminates gosuranemab in progressive surpanuclear palsy following Phase 2 failure

December 16, 2019 Research and Development, Sales and Marketing Biogen, pharma, trial failure

Biogen has revealed its intention to shut down further development of gosuranemab after results of a Phase 2 study showed …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

December 13, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top ten

As the UK reels from the news that Boris Johnson and the Conservative Party have stormed the general election and …
News
roche

Roche’s subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer

December 12, 2019 Research and Development Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma

New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertuzumab) and Herceptin (trastuzumab), in combination …
News
shutterstock_512649

New NAFTA terms put hold on Canadian drug prices

December 11, 2019 Research and Development, Sales and Marketing Canada, NAFTA, US, pharma

NAFTA members have agreed to remove a provision that would have increased protections on biologics drugs. This means Canada, despite …
News
6127243966_e9189f1099_b

Multiple sclerosis market to be worth $32.9bn in 2028

December 11, 2019 Research and Development Big Pharma, MS, MS treatement, multiple sclerosis, pharma

The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 …
News
fdaoutsideweb

Correvio’s atrial fibrillation drug voted down by FDA committee over safety concerns

December 11, 2019 Research and Development, Sales and Marketing Correvio Pharma, FDA, atrial fibrillation, pharma

It has emerged that Correvio Pharma’s anti-arrhythmic therapy Brinavess was shot down by the FDA’s Cardiovascular and Renal Drugs Advisory …
News
avian_influenza__bird_flu__sign_-_geograph

27,000 chickens to be culled after UK bird flu outbreak

December 11, 2019 Research and Development Bird Flu, Chicken Flu, Swin Flu, influenza, influenza b

A chicken farm in Suffolk has been confirmed by the British government to have cases of bird flu. 27,000 birds …
News

Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia

December 11, 2019 Research and Development ASH 19, Bristol-Myers Squibb, acute myeloid leukaemia, pharma

Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data …
News
china_block_001_takeda_0

Takeda commits to advancing treatments for rare bleeding disorders and cancer

December 10, 2019 Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology

Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to …
News
janssen_latest_logo_on_sign

Janssen’s Darzalex combo shows strong overall survival benefit at ASH 2019

December 10, 2019 Manufacturing and Production, Research and Development ASH 19, Janssen, darzalex, pharma

Janssen has unveiled new Phase 3 data on the efficacy of Darzalex (daratumumab) when combined with bortezomib, melphalan and prednisone …
News
abbvie_0

Strong four-year follow-up data revealed for AbbVie’s venetoclax combo in chronic lymphocytic leukaemia

December 9, 2019 Research and Development, Sales and Marketing ASH 2019, AbbVie, chronic lymphocytic leukaemia, pharma, venetoclax

AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax …
News
shutterstock_138095450

Transactions in the pharma sector: Through the EU merger review looking-glass

December 9, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, feature, mergers & acquisitions, pharma

With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …
Feature
jj

J&J’s CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma

December 9, 2019 Research and Development, Sales and Marketing ASH 2019, CAR-T, J&J, JJ, Johnson & Johnson, pharma

Johnson & Johnson were present at the American Society of Hematology (ASH) Annual Meeting over the weekend to unveil new …
News
sage_logo

Sage Therapeutics’ depression drug falls short at Phase 3

December 6, 2019 Medical Communications, Research and Development Sage Therapeutics, major depressive disorder, pharma, trial failure

Sage Therapeutics has announced that its candidate SAGE-217 flopped in Phase 3 trials investigating its efficacy in symptom reduction for …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026